MOLN — MOLECULAR PARTNERS AG
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1745114 ·
Last close
$3.93
Market Cap
$147.42M
52W High
$4.52
52W Low
$3.66
ADV30
6,080
Next earnings
2026-08-25
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -13,443,000 | -13,144,000 | 87,658,000 | 64,251,000 | 19,206,000 |
| Dec 2025 | 0 | — | -12,667,000 | -12,649,000 | 102,107,000 | 82,653,000 | 21,773,000 |
| Sep 2025 | 0 | — | -11,930,000 | -11,836,000 | 112,150,000 | 82,359,000 | 16,621,000 |
| Jun 2025 | 0 | — | -14,700,000 | -20,398,000 | 124,252,000 | 81,975,000 | 17,591,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,255,000
Investing CF
$72,549,000
Financing CF
$-1,149,000
CapEx
$-714,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.83
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-311,753,000
Inventory
—
Receivables
$1,905,000
ST Investments
$10,405,000
EBIT TTM
$-61,633,000
Pretax Income TTM
$-61,651,000
Interest Exp TTM
$18,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -55,436,000 | -61,651,000 | 102,107,000 | 21,773,000 | — | -51,257,000 |
| Dec 2024 | 4,970,000 | -61,217,000 | -54,043,000 | 158,528,000 | 16,891,000 | — | -59,248,000 |
| Dec 2023 | 7,038,000 | -61,108,000 | -61,984,000 | 198,352,000 | 21,923,000 | — | -59,005,000 |
| Dec 2022 | 189,556,000 | 116,613,000 | 117,853,000 | 262,258,000 | 27,092,000 | — | 118,566,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.26
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENTX | Entera Bio Ltd. | $147.38M | $2.99 | — |
| CRDL | Cardiol Therapeutics Inc. | $146.40M | $1.27 | — |
| CRBU | Caribou Biosciences, Inc. | $144.80M | $1.46 | — |
| IPHYF | Innate Pharma SA | $154.94M | $1.65 | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $155.29M | $2.15 | — |
News headlines (Yahoo Finance, 1h cache)
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
2026-07-16 05:00 · Yahoo
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
2026-07-15 05:00 · Yahoo
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
2026-07-06 05:00 · Yahoo
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
2026-07-02 05:00 · Yahoo
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
2026-05-30 12:00 · Yahoo
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
2026-05-26 20:00 · Yahoo
Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ...
2026-05-14 01:03 · Yahoo
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
2026-05-12 20:00 · Yahoo
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
2026-05-04 05:00 · Yahoo
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
2026-05-01 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.